The buccal drug delivery system market size has grown rapidly in recent years. It will grow from $3.89 billion in 2025 to $4.32 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing preference for alternative drug delivery routes, growth in chronic pain and angina treatments, advancements in mucoadhesive formulations, rising demand for faster onset medications, expansion of oral pharmaceutical manufacturing.
The buccal drug delivery system market size is expected to see rapid growth in the next few years. It will grow to $6.48 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing investments in transmucosal drug research, rising demand for smoking cessation therapies, expansion of personalized drug delivery systems, growing focus on compliance-friendly formulations, increasing development of novel buccal drugs. Major trends in the forecast period include increasing adoption of buccal and sublingual dosage forms, rising demand for rapid drug absorption systems, growing focus on patient-friendly drug delivery, expansion of controlled-release buccal formulations, enhanced emphasis on non-invasive therapies.
The increasing prevalence of chronic diseases is anticipated to boost the growth of the buccal drug delivery systems market in the future. Chronic diseases are defined as health conditions that last for a year or more, including cancer, heart disease, stroke, diabetes, and arthritis. These illnesses are among the most common chronic conditions that can be managed but not cured, requiring ongoing medical care and nutrition. Buccal drug delivery systems offer an effective and suitable method for administering mucosal and transmucosal drugs needed by many patients suffering from chronic diseases such as diabetes and cancer. For instance, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths, accounting for 74% of global deaths caused by non-communicable diseases (NCDs) or chronic diseases, occur each year. Among these, there were 17.9 million deaths due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Thus, the increasing prevalence of chronic diseases is driving the growth of the buccal drug delivery systems market.
Leading players in the buccal drug delivery systems space are emphasizing new product introductions, such as melatonin oral sprays, to support revenue growth. A melatonin oral spray is a melatonin supplement delivered in a spray form for oral administration, enabling convenient and efficient use. For example, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical company, introduced a melatonin oral spray. The product supports the body’s natural melatonin production, helping to enhance sleep quality through a simple and effective delivery method. It provides rapid relief for individuals experiencing difficulty falling asleep, staying asleep, or adapting to changing sleep schedules. Owing to its fast and easy oral absorption, the spray enables a quicker onset of sleep and contributes to improved overall sleep quality.
In April 2023, DifGen Pharmaceuticals LLC, a United States-based pharmaceutical company, acquired Aveva Drug Delivery Services Inc. for an undisclosed consideration. The transaction was intended to enhance patient access to essential, life-saving medicines that are consistently high in quality and offered at affordable costs. This acquisition enabled DifGen to strengthen its research and development and manufacturing capabilities, while supporting a secure supply chain and the production of complex dosage forms for its partners through localized manufacturing operations in the United States. Aveva Drug Delivery Services Inc. is a United States-based company specializing in buccal drug delivery system solutions.
Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc.
North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in the buccal drug delivery system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the buccal drug delivery system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the buccal drug delivery system market by increasing costs of imported pharmaceutical excipients, packaging materials, specialized manufacturing equipment, and quality testing instruments. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported formulation inputs, while Asia-Pacific faces cost pressure on finished product exports. These tariffs are increasing production costs and extending development timelines. However, they are also supporting local excipient production, regional manufacturing expansion, and innovation in cost-efficient formulation technologies.
The buccal drug delivery system market research report is one of a series of new reports that provides buccal drug delivery system market statistics, including buccal drug delivery system industry global market size, regional shares, competitors with a buccal drug delivery system market share, detailed buccal drug delivery system market segments, market trends and opportunities, and any further data you may need to thrive in the buccal drug delivery system industry. This buccal drug delivery system market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The buccal drug delivery system involves administering the desired medicine through the buccal mucosal membrane lining of the mouth cavity. This method is effective for delivering mucosal and transmucosal drugs. Mucosal drug delivery aims for site-specific drug release on the mucosa, whereas transmucosal permeation entails drug absorption across the mucosal barrier and into the systemic circulation.
The main types of buccal drug delivery systems include sublingual, buccal tablets and lozenges, and oral sprays. The term sublingual refers to the route of administration for systemic medication delivery of buccal drugs. These are applied in various applications such as pain management, smoking cessation, and angina pectoris, and are utilized by hospitals, ambulatory care centers, and other healthcare facilities.
The buccal drug delivery system market consists of the sales of drug ingredients such as insulin, nicotine, tizanidine, triptan, nifedipine, flurbiprofen, sodium carboxymethylcellulose, carbopol, glibenclamide, hyaluronic acid, and xanthan gum. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The buccal drug delivery system market size is expected to see rapid growth in the next few years. It will grow to $6.48 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing investments in transmucosal drug research, rising demand for smoking cessation therapies, expansion of personalized drug delivery systems, growing focus on compliance-friendly formulations, increasing development of novel buccal drugs. Major trends in the forecast period include increasing adoption of buccal and sublingual dosage forms, rising demand for rapid drug absorption systems, growing focus on patient-friendly drug delivery, expansion of controlled-release buccal formulations, enhanced emphasis on non-invasive therapies.
The increasing prevalence of chronic diseases is anticipated to boost the growth of the buccal drug delivery systems market in the future. Chronic diseases are defined as health conditions that last for a year or more, including cancer, heart disease, stroke, diabetes, and arthritis. These illnesses are among the most common chronic conditions that can be managed but not cured, requiring ongoing medical care and nutrition. Buccal drug delivery systems offer an effective and suitable method for administering mucosal and transmucosal drugs needed by many patients suffering from chronic diseases such as diabetes and cancer. For instance, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths, accounting for 74% of global deaths caused by non-communicable diseases (NCDs) or chronic diseases, occur each year. Among these, there were 17.9 million deaths due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Thus, the increasing prevalence of chronic diseases is driving the growth of the buccal drug delivery systems market.
Leading players in the buccal drug delivery systems space are emphasizing new product introductions, such as melatonin oral sprays, to support revenue growth. A melatonin oral spray is a melatonin supplement delivered in a spray form for oral administration, enabling convenient and efficient use. For example, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical company, introduced a melatonin oral spray. The product supports the body’s natural melatonin production, helping to enhance sleep quality through a simple and effective delivery method. It provides rapid relief for individuals experiencing difficulty falling asleep, staying asleep, or adapting to changing sleep schedules. Owing to its fast and easy oral absorption, the spray enables a quicker onset of sleep and contributes to improved overall sleep quality.
In April 2023, DifGen Pharmaceuticals LLC, a United States-based pharmaceutical company, acquired Aveva Drug Delivery Services Inc. for an undisclosed consideration. The transaction was intended to enhance patient access to essential, life-saving medicines that are consistently high in quality and offered at affordable costs. This acquisition enabled DifGen to strengthen its research and development and manufacturing capabilities, while supporting a secure supply chain and the production of complex dosage forms for its partners through localized manufacturing operations in the United States. Aveva Drug Delivery Services Inc. is a United States-based company specializing in buccal drug delivery system solutions.
Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc.
North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in the buccal drug delivery system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the buccal drug delivery system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the buccal drug delivery system market by increasing costs of imported pharmaceutical excipients, packaging materials, specialized manufacturing equipment, and quality testing instruments. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported formulation inputs, while Asia-Pacific faces cost pressure on finished product exports. These tariffs are increasing production costs and extending development timelines. However, they are also supporting local excipient production, regional manufacturing expansion, and innovation in cost-efficient formulation technologies.
The buccal drug delivery system market research report is one of a series of new reports that provides buccal drug delivery system market statistics, including buccal drug delivery system industry global market size, regional shares, competitors with a buccal drug delivery system market share, detailed buccal drug delivery system market segments, market trends and opportunities, and any further data you may need to thrive in the buccal drug delivery system industry. This buccal drug delivery system market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The buccal drug delivery system involves administering the desired medicine through the buccal mucosal membrane lining of the mouth cavity. This method is effective for delivering mucosal and transmucosal drugs. Mucosal drug delivery aims for site-specific drug release on the mucosa, whereas transmucosal permeation entails drug absorption across the mucosal barrier and into the systemic circulation.
The main types of buccal drug delivery systems include sublingual, buccal tablets and lozenges, and oral sprays. The term sublingual refers to the route of administration for systemic medication delivery of buccal drugs. These are applied in various applications such as pain management, smoking cessation, and angina pectoris, and are utilized by hospitals, ambulatory care centers, and other healthcare facilities.
The buccal drug delivery system market consists of the sales of drug ingredients such as insulin, nicotine, tizanidine, triptan, nifedipine, flurbiprofen, sodium carboxymethylcellulose, carbopol, glibenclamide, hyaluronic acid, and xanthan gum. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Buccal Drug Delivery System Market Characteristics
3. Buccal Drug Delivery System Market Supply Chain Analysis
4. Global Buccal Drug Delivery System Market Trends and Strategies
5. Buccal Drug Delivery System Market Analysis of End Use Industries
7. Global Buccal Drug Delivery System Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Buccal Drug Delivery System Total Addressable Market (TAM) Analysis for the Market
9. Buccal Drug Delivery System Market Segmentation
10. Buccal Drug Delivery System Market Regional and Country Analysis
11. Asia-Pacific Buccal Drug Delivery System Market
12. China Buccal Drug Delivery System Market
13. India Buccal Drug Delivery System Market
14. Japan Buccal Drug Delivery System Market
15. Australia Buccal Drug Delivery System Market
16. Indonesia Buccal Drug Delivery System Market
17. South Korea Buccal Drug Delivery System Market
18. Taiwan Buccal Drug Delivery System Market
19. South East Asia Buccal Drug Delivery System Market
20. Western Europe Buccal Drug Delivery System Market
21. UK Buccal Drug Delivery System Market
22. Germany Buccal Drug Delivery System Market
23. France Buccal Drug Delivery System Market
24. Italy Buccal Drug Delivery System Market
25. Spain Buccal Drug Delivery System Market
26. Eastern Europe Buccal Drug Delivery System Market
27. Russia Buccal Drug Delivery System Market
28. North America Buccal Drug Delivery System Market
29. USA Buccal Drug Delivery System Market
30. Canada Buccal Drug Delivery System Market
31. South America Buccal Drug Delivery System Market
32. Brazil Buccal Drug Delivery System Market
33. Middle East Buccal Drug Delivery System Market
34. Africa Buccal Drug Delivery System Market
36. Buccal Drug Delivery System Market Competitive Landscape and Company Profiles
37. Buccal Drug Delivery System Market Other Major and Innovative Companies
40. Buccal Drug Delivery System Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Buccal Drug Delivery System Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses buccal drug delivery system market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for buccal drug delivery system? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The buccal drug delivery system market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Sublingual; Buccal Tablets And Lozenges; Oral Sprays2) By Application: Pain Management; Smoking Cessation; Angina Pectoris
3) By End-User: Hospitals; Ambulatory Centers; Other End-Users
Subsegments:
1) By Sublingual: Sublingual Tablets; Sublingual Films2) By Buccal Tablets And Lozenges: Buccal Tablets; Buccal Lozenges
3) By Oral Sprays: Spray Solutions; Spray Gels
Companies Mentioned: Teva Pharmaceuticals Industries Ltd; Pfizer Incorporated; GlaxoSmithKline Public Limited Company; Indivior PLC; Generex Biotechnology Corporation; Catalent Inc; Arx Limited Liability Company; BioDelivery Science International Incorporated; Cynapsus Therapeutics Incorporated; Endo Pharmaceuticals Public Limited Company; Medlab Clinical Ltd; AstraZeneca PLC; Dr. Reddy’s Laboratories Ltd; Takeda Pharmaceutical Company Limited; Novartis AG; Sanofi SA; Bayer AG; Adare Pharmaceuticals Inc; NAPP Pharmaceutical Ltd; Perrigo Company PLC; Reckitt Benckiser Group PLC; Teligent Pharma Inc; Par Pharmaceutical Companies Inc; Acorda Therapeutics Inc; Opiant Pharmaceuticals Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Buccal Drug Delivery System market report include:- Teva Pharmaceuticals Industries Ltd
- Pfizer Incorporated
- GlaxoSmithKline Public Limited Company
- Indivior PLC
- Generex Biotechnology Corporation
- Catalent Inc
- Arx Limited Liability Company
- BioDelivery Science International Incorporated
- Cynapsus Therapeutics Incorporated
- Endo Pharmaceuticals Public Limited Company
- Medlab Clinical Ltd
- AstraZeneca PLC
- Dr. Reddy’s Laboratories Ltd
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Sanofi SA
- Bayer AG
- Adare Pharmaceuticals Inc
- NAPP Pharmaceutical Ltd
- Perrigo Company PLC
- Reckitt Benckiser Group PLC
- Teligent Pharma Inc
- Par Pharmaceutical Companies Inc
- Acorda Therapeutics Inc
- Opiant Pharmaceuticals Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.32 Billion |
| Forecasted Market Value ( USD | $ 6.48 Billion |
| Compound Annual Growth Rate | 10.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
